Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • FDA
  • News

GSK Announces U.S. FDA Approval of Benlysta (Belimumab) For Pediatric Patients With Active Lupus Nephritis

By Benzinga Newsdesk
July 27, 1:20 PM
GSK plc (NYSE:GSK) today announced that the US Food and Drug Administration (FDA) has approved Benlysta (belimumab) for the treatment of children aged 5 to 17 with active lupus nephritis (LN) who are receiving

GSK

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • General
  • Health Care
  • Initiation
  • M&A
  • News
  • Price Target

This Analyst Says GSK Spin-Off Haleon Offers “Best Of Both Consumer Worlds”

By Vandana Singh
July 22, 2:06 PM
Citi group has initiated coverage on GSK plc's (NYSE: GSK) consumer healthcare spin-off Haleon Plc (NYSE: HLN) with a Buy rating and a price target of 360p.

GSK

Read More
2 minute read
  • Biotech
  • Eurozone
  • General
  • Global
  • M&A
  • Markets
  • News

Post Mega London Stock Exchange Listing, GSK Spinoff Haleon’s Plunge Brings Valuation Concerns To The Fore

By Bhavik Nair
July 19, 4:06 AM
After GSK (NYSE: GSK) spun off its consumer health division Haleon Plc (LSE: HLN) into a separate entity, shares of the newly listed firm plunged during intraday trade, closing over 6.5% down at GBX 308.4 on the London Stock Exchange on Monday.

GLNCY

Read More
1 minute read
  • Movers
  • News
  • Small Cap
  • Trading Ideas

Codexis Shares Slide On CEO Transition

By Akanksha Bakshi
July 18, 4:52 PM
Codexis, Inc. (NASDAQ:CDXS) has appointed Dr. Stephen Dilly, Board member, and biotechnology veteran, as President and CEO, effective August 9,…

CDXS

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • M&A
  • News

GSK Completes Spin Off Of Its Consumer Healthcare Business

By Vandana Singh
July 18, 7:41 AM
GSK plc (NYSE:GSK) has completed the demerger of the Consumer Healthcare business to form the Haleon Group.  Reuters reported that shares in…

GSK

Read More
1 minute read
  • M&A
  • Movers
  • News
  • Small Cap
  • Trading Ideas

Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests

By Akanksha Bakshi
July 13, 5:29 PM
Theravance Biopharma, Inc. (NASDAQ:TBPH) has agreed to sell all of its units in Theravance Respiratory Company, LLC, representing 85% economic…

GSK

Read More
5 minute read
  • Exclusives
  • General
  • News
  • SPACE

Science Wednesday: Where To See Comet K2 As It Passes The Earth

By Phil Hall
July 13, 10:08 AM
Five years ago, astronomers were electrified to confirm the discovery of Comet C/2017 K2, more commonly known as Comet K2. At the time, it was believed to be one of the largest comets zooming across the universe, with a nucleus believed to be around 11 miles in diameter and a tail measuring a ginormous 500,000 miles long.

GSK

Read More
5 minute read
  • FDA
  • News

GSK Prepares Us For 2022-23 Flu Season With Over 50M Influenza Vaccine Doses

By Benzinga Newsdesk
July 11, 3:27 PM
GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses GSK begins shipping FLULAVAL QUADRIVALENT and FLUARIX QUADRIVALENT GSK plc (NYSE:GSK) today announced it has started shipping doses of

GSK

Read More
1 minute read
  • News

GSK Says Regulatory Submission For Co’s Daprodustat Accepted Into Health Canada Review

By Benzinga Newsdesk
July 6, 12:34 PM
-Reuters

GSK

Posts pagination

Previous 1 … 28 29
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service